Dataset Information

Comparative proteomic analysis without a label based on the technology of tandem HPLC - MS/MS

ABSTRACT: The relative differences between post-translational modifications (PTM) of proteins in blood plasma samples of patients with cerebral ischemia (CI) and healthy people were investigated on the basis of the method of comparative proteomic analysis without a label based on the technology of tandem HPLC - MS/MS. For the detection of PTM, we used multiple search MS / MS in the database Mascot installed variable PTM and Progenesis LS-MS software. In the CI plasma, we observed an increase in the share of posttranslation modified peptides. Such PTM proteins as phosphorylation of serine, threonine and tyrosine, acetylation of lysine and N-terminal protein, ubiquitination of lysine and deamidation of glutamine related to clinically significant processes were revealed.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

DISEASE(S): Brain Ischemia

SUBMITTER: Ekaterina Ilgisonis

LAB HEAD: Irina Karuzina

PROVIDER: PXD012974 | Pride | 2019-12-04

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 54

Publications

[Comparative analysis of post-translational modifications in plasma proteome of patients with cerebral ischemia based on HPLC-MS/MS method].

Kisrieva Y S YS Petushkova N A NA Samenkova N F NF Kuznetsova G P GP Larina O B OB Teryaeva N B NB Usachev D Yu DY Zgoda V G VG Karuzina I I II

Biomeditsinskaia khimiia 20190401 3

The relative differences between post-translational modifications (PTM) of proteins in blood plasma samples of patients with cerebral ischemia (CI) and healthy people were investigated using of the method of label-free comparative proteomic analysis based on the technology of tandem HPLC-MS/MS. For PTM detection we used multiple MS/MS search in the database Mascot for variable PTM and Progenesis LS-MS software. In the CI plasma samples, we observed an increase in the proportion of peptides with ...[more]

PMID: 31258150

Similar Datasets

Project description:Purpose: We generated extensive transcriptional and proteomic profiles from a Her2-driven mouse model of breast cancer that closely recapitulates human breast cancer. This report makes these data publicly available in raw and processed forms, as a resource to the community. Importantly, we previously made biospecimens from this same mouse model freely available through a sample repository, so researchers can obtain samples to test biological hypotheses without the need of breeding animals and collecting biospecimens. Experimental design: Twelve datasets are available, encompassing 841 LC-MS/MS experiments (plasma and tissues) and 255 microarray analyses of multiple tissues (thymus, spleen, liver, blood cells, and breast). Cases and controls were rigorously paired to avoid bias. Results: In total, 18,880 unique peptides were identified (PeptideProphet peptide error rate â¤1%), with 3884 and 1659 non-redundant protein groups identified in plasma and tissue datasets, respectively. Sixty-one of these protein groups overlapped between cancer plasma and cancer tissue. Conclusions and clinical relevance: These data are of use for advancing our understanding of cancer biology, for software and quality control tool development, investigations of analytical variation in MS/MS data, and selection of proteotypic peptides for MRM-MS. The availability of these datasets will contribute positively to clinical proteomics. Affymetrix GeneChip Mouse Genome 430 2.0 microarrays were used to profile whole tissues from 5 different tissue types of 25 tumor-bearing and 25 control mice of the Her2/Neu breast cancer mouse model. The 5 tissues tested were from breast, liver, spleen, blood cell, and thymus. The tumor-bearing mice were bitransgenic for MMTV-rtTA/TetO-NeuNT, and the control mice were transgenic for TetO-NeuNT only. The control mice were age- and cage-matched to the tumor-bearing mice. All samples were lysed and total RNA isolated and amplified prior to hybridization.

			Action	DRS
	170616ONA_01.mgf	Mgf
	170616ONA_01.raw	Raw
	170616ONA_01_160621002248.mgf	Mgf
	170616ONA_01_160621002248.raw	Raw
	170616ONA_01_160621015438.mgf	Mgf